论文部分内容阅读
瑞格列奈 (repaglinide)是新一代的非磺脲类的胰岛素刺激剂 ,其单独治疗 2型糖尿病优势已在中国多家医院得到验证 ,但与二甲双胍 (metformin)联用尚未见报道 ,我们用于临床取得良好的疗效。1 对象与方法1.1 病例选择均为 2 0 0 0年 11月～ 2 0 0 1年 3月在我科住院的 2型糖尿
Repaglinide, a new generation of non-sulfonylurea insulin stimulants, has been validated at several hospitals in China for its unique efficacy in treating type 2 diabetes. However, the combination with metformin has not been reported. In clinical achieved good effect. 1 objects and methods 1.1 case selection are 2000 November 2001 ~ March 2001 hospitalized in our department of type 2 diabetes